Zymeworks Inc (ZYME) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with ZYME
Recent news
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
ZYME
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
ZYME
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
ZYME
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
ZYMENews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.00
- MACD 12/26/9
- -0.32
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.17
- SMA 50
- $26.43
- Price below SMA 50
- EMA 50
- $26.37
- Price below EMA 50
- SMA 200
- $25.09
- Price above SMA 200
- EMA 200
- $24.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.22 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
ZYMESJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
ZYMEJAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
ZYMEJAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
ZYME
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
ZYME
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
ZYME
Theravance Stock Down 3% After Zymeworks Announces Buyout
Theravance Stock Down 3% After Zymeworks Announces Buyout
ZYME
Zymeworks strikes $929 million deal for Theravance Biopharma
Zymeworks strikes $929 million deal for Theravance Biopharma
ZYME
Zymeworks Q1 Earnings Call Highlights
Zymeworks Q1 Earnings Call Highlights
ZYME
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
ZYMENews tone: automated (AI) classification of the article's content, not a price prediction.
About Zymeworks Inc
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenneth H. Galbraith C.A. | Chairman of the Board, CEO & President | 1962 |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer | 1967 |
| Mr. Scott Platshon B.S. | Executive VP & Chief Business Officer | 1991 |
| Ms. Kristin Stafford CPA | Executive VP & CFO | 1982 |
| Mr. Mark Hollywood | Executive VP & COO | 1969 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 43.00
- MACD 12/26/9
- -0.32
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.17
- SMA 50
- $26.43
- Price below SMA 50
- EMA 50
- $26.37
- Price below EMA 50
- SMA 200
- $25.09
- Price above SMA 200
- EMA 200
- $24.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $32.00
- Average
- $39.57
- High
- $55.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.3 | -14.1 | -19.0 | |||||||||
| 2022 | -47.6 | -13.9 | -4.9 | -8.3 | -2.2 | -24.1 | +5.4 | +7.9 | -4.9 | +25.1 | +3.6 | +1.7 |
| 2023 | +25.3 | -11.3 | +12.9 | -10.4 | -2.4 | +1.8 | -13.1 | -2.8 | -15.4 | +13.4 | +26.4 | +13.6 |
| 2024 | +4.4 | +9.4 | -15.9 | -13.2 | -3.2 | +0.9 | +21.5 | +16.0 | +8.9 | +10.9 | +6.1 | +1.0 |
| 2025 | -1.2 | -8.8 | -6.5 | +12.0 | -11.3 | +7.8 | +1.2 | +17.8 | +21.9 | +12.7 | +41.4 | +1.2 |
| 2026 | -15.4 | +0.5 | +7.4 | +6.2 | -5.6 | +6.5 | -14.7 | +34.8 | -10.7 | -2.7 |
